% 0期刊文章%露丝多布森% Richard A . Rudick %本特纳%一个Gavin Giovannoni克劳斯主要% % T评估治疗反应interferon-β% B核磁共振的作用吗?% D R 10.1212 / WNL 2014%。0000000000000036 % J首页神经病学% P 248 - 254 X % V 82% N 3%目的:Interferon-β(IFN-β)已经被证明可以减少复发率在多发性硬化;然而,临床反应似乎个体之间的不同。早期MRI可以用来识别患者对治疗的反应不佳?方法:系统回顾研究微分治疗反应和临床端点定义为一组反应或nonresponders IFN-β。整合技术被用来在适当的地方结合研究结果。结果:患者MRI的证据贫穷回应IFN-β治疗≥2定义的新hyperintense T2病灶钆增强病变或新的风险明显增加未来的复发和进展所定义的规模扩大残疾状况。似乎有一个糟糕的结果的风险增加16年治疗后开始的,最初对治疗的反应不佳。之前的证据表明这并非如此在安慰剂的临床试验。Conclusions: For those patients starting IFN-β, early MRI, within 6 to 24 months after starting treatment, has the potential to provide important information when counseling patients about the likelihood of future treatment failure. This can inform treatment decisions before clinical relapses or disease progression.CDMS=clinically definite multiple sclerosis; CI=confidence interval; CIS=clinically isolated syndrome; EDSS=Expanded Disability Status Scale; IFN-β=interferon-β; MS=multiple sclerosis; MSFC=Multiple Sclerosis Functional Composite; NAb=neutralizing antibody; OR=odds ratio %U //www.ez-admanager.com/content/neurology/82/3/248.full.pdf